2006
DOI: 10.1186/cc5006
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Introduction Hospital-acquired pneumonia (HAP) due to Pseudomonas aeruginosa is associated with high mortality rates. The metallo-β-lactamases (MBLs) are emerging enzymes that hydrolyze virtually all β-lactams. We aimed to assess P. aeruginosa HAP mortality in a setting of high-rate MBL production

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

3
15
0

Year Published

2009
2009
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(18 citation statements)
references
References 18 publications
3
15
0
Order By: Relevance
“…There are several factors related to biofilm formation, the main are: physico-chemical features of the material on which it is adhered and expression of virulence factors by the micro-organisms, as exopolymeric capsule production and fimbrial and non-fimbrial adhesins synthesis [41].…”
Section: Discussionmentioning
confidence: 99%
“…There are several factors related to biofilm formation, the main are: physico-chemical features of the material on which it is adhered and expression of virulence factors by the micro-organisms, as exopolymeric capsule production and fimbrial and non-fimbrial adhesins synthesis [41].…”
Section: Discussionmentioning
confidence: 99%
“…In addition, individuals with cystic fibrosis (CF) are highly susceptible to chronic pseudomonal lung infections (5,6), and the pathogen plays a critical role in the morbidity and mortality of CF patients (7). The rate of mortality of patients infected nosocomially with P. aeruginosa is very high, with rates reported to be from ϳ30 to 50% (8)(9)(10). The emergence of clinical isolates of P. aeruginosa that exhibit resistance to one or more antibiotics, including fluoroquinolones, carbapenems, and a fourth-generation cephalosporin (cefepime) that is currently the antibiotic of choice for pseudomonal infections (11), severely limits treatment options (12)(13)(14)(15)(16)(17).…”
mentioning
confidence: 99%
“…At even higher bacterial inocula, as seen in bacterial ventilator-associated pneumonia (VAP) (47), achieving high colistin concentrations against more-difficult-to-treat polymyxin-heteroresistant strains may pose a formidable challenge. Bergen et al investigated the combination of colistin plus doripenem against P. aeruginosa in vitro, simulating colistin pharmacokinetics obtained from critically ill patients (35).…”
Section: Discussionmentioning
confidence: 99%